Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Simcere Pharmaceutical Group Limited ( (HK:2096) ) just unveiled an announcement.
Simcere Pharmaceutical Group Limited, a Hong Kong-listed drug maker, operates in the healthcare and life sciences industry with a focus on the research, development, manufacture and commercialization of pharmaceutical products. The company targets patients and healthcare providers through a range of therapeutic offerings and maintains a governance structure led by Chairman and executive director Ren Jinsheng alongside a board of executive and independent non-executive directors.
The company announced a proposed final ordinary cash dividend of RMB 0.18 per share for the financial year ended 31 December 2025, with shareholder approval scheduled for 12 June 2026. The dividend, to be paid in Hong Kong dollars at an exchange rate yet to be announced, will go ex-dividend on 17 June 2026, use a record date of 24 June 2026 following a 19–24 June book closure, and is expected to be paid on 13 July 2026, underscoring the group’s intention to return cash to shareholders.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company focused on researching, developing, manufacturing and commercializing medicines. The group operates in the broader healthcare and life sciences industry, serving patients and healthcare providers through its portfolio of drug products and related therapies.
Average Trading Volume: 6,403,851
Technical Sentiment Signal: Buy
Current Market Cap: HK$28.76B
See more data about 2096 stock on TipRanks’ Stock Analysis page.